ClinicalTrials.gg
CompletedNCT04436497Updated Jul 25, 2023Results posted

HEALEY ALS Platform Trial - Regimen A Zilucoplan

A Phase 2/3 interventional study of Zilucoplan and Matching Placebo in Amyotrophic Lateral Sclerosis, sponsored by Merit E. Cudkowicz, MD. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-25.

Sponsored by Merit E. Cudkowicz, MD · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.

Enrollment
48th of 307
162 · median 33
Started
2020
with 28 others
Phase 2/3
18 of 440
1 open now
Registered
264th of 440
by date
Lead sponsor
9 of 440
Merit E. Cudkowicz, MD

Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 48th largest by enrollment of the 307 interventional ones that give a count, is one of 29 that started in 2020, is one of 18 in phase 2/3, and was the 264th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, or all of them as a file.
02

Study summary

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.

Regimen A will evaluate the safety and efficacy of a single study drug, zilucoplan, in participants with ALS.

Read the detailed description

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. This trial is designed as a perpetual platform trial. This means that there is a single Master Protocol dictating the conduct of the trial. The HEALEY ALS Platform Trial Master Protocol is registered as NCT04297683.

Once a participant enrolls into the Master Protocol and meets all eligibility criteria, the participant will be eligible to be randomized into any currently enrolling regimen. All participants will have an equal chance of being randomized to any currently enrolling regimen.

If a participant is randomized to Regimen A - Zilucoplan, the participant will complete a screening visit to assess additional Regimen A eligibility criteria. Once Regimen A eligibility criteria are confirmed, participants will complete a baseline assessment and be randomized in a 3:1 ratio to either active zilucoplan or matching placebo.

Regimen A will enroll by invitation, as participants may not choose to enroll in Regimen A. Participants must first enroll into the Master Protocol and be eligible to participate in the Master Protocol before being able to be randomly assigned to Regimen A.

For a list of enrolling sites, please see the HEALEY ALS Platform Trial Master Protocol under NCT04297683.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis

Keywords

  • ALS
  • Placebo-Controlled
  • Double-Blind
  • Regimen-Specific Appendix
  • Lou Gehrig's Disease
  • Zilucoplan
  • Ra Pharmaceuticals
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The following inclusion criterion is in addition to the inclusion criteria specified in the Master Protocol (NCT NCT04297683).

    1. Vaccination with a quadrivalent meningococcal vaccine and meningococcal serotype B vaccine at least 14 days prior to the first dose of study drug at the Baseline (Day 0) visit. Meningococcal vaccines (including boosters) should be administered in accordance with the study's vaccination worksheet.

Exclusion criteria

Exclusion Criteria:

  • The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683).

    1. History of meningococcal disease.
    2. Prior treatment with a complement inhibitor.
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
162 participants (actual)

Study arms

  • Experimental
    Zilucoplan

    Drug: Zilucoplan Administration: Subcutaneous injection Dosage: 0.3mg/kg administered daily

    Drug: Zilucoplan

  • Placebo comparator
    Matching Placebo

    Administration: Subcutaneous injection Dosage: Daily subcutaneous injection

    Drug: Matching Placebo

Interventions

  • Drug: Zilucoplan Administration: Subcutaneous injection Dosage: 0.3mg/kg administered daily

  • DrugMatching Placebo

    Drug: Matching Placebo Administration: Subcutaneous injection Dosage: Daily subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Disease Progression as Assessed by the ALSFRS-R Total Score

    Change in disease severity as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) total score using a Bayesian repeated measures model that accounts for loss to follow-up due to mortality. Each of 12 questions assessing distinct functional ability is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.

    Time frame: Baseline through 24 Weeks

  2. Mortality Event Rate

    Mortality is defined as death or death equivalent. A participant is determined to meet the criteria of death equivalent if permanent assisted ventilation (PAV) is used for more than 22 hours per day for more than seven days in a row. The rate of mortality was estimated from a Bayesian shared-parametric model that assumed exponentially distributed survival times.

    Time frame: Baseline through 24 Weeks

Secondary outcomes

  1. Respiratory Function

    Change in respiratory function as assessed by slow vital capacity (SVC).

    Time frame: Baseline and 24 Weeks

  2. Muscle Strength

    Change in muscle strength as measured isometrically using hand-held dynamometry (HHD).

    Time frame: Baseline and 24 Weeks

  3. Number of Participants That Experienced Death or Death Equivalent

    The number of participants who died or met the criterion for a death equivalent from the date of their baseline visit to the end of the Week 24 visit window (generally 175 days after baseline). The death equivalent criterion is use of permanent assisted ventilation (PAV) for more than 22 hours per day for more than 7 days in a row.

    Time frame: Baseline through 24 Weeks

07

Results

Posted Jul 25, 2023

Participant flow

Participant flow — Overall Study
MilestoneZilucoplanMatching Placebo
Started12240
Completed8829
Not completed3411

Outcome measures

PrimaryDisease Progression as Assessed by the ALSFRS-R Total Score

Change in disease severity as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) total score using a Bayesian repeated measures model that accounts for loss to follow-up due to mortality. Each of 12 questions assessing distinct functional ability is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.

Time frame:
Baseline through 24 Weeks
Reported as:
Mean · ALSFRS-R total score points per month
Disease Progression as Assessed by the ALSFRS-R Total Score
ALSFRS-R total score points per monthZilucoplanMatching Placebo
Disease Progression as Assessed by the ALSFRS-R Total Score-1.11 ± 0.083-1.03 ± 0.072
Statistical analysis
  • Zilucoplan vs Matching Placebo · Bayesian shared-parameter model · Disease rate ratio: 1.08 · 95% CI 0.874 to 1.307DDR \<1 imply slowing of disease progression by zilucoplan relative to placebo. Note: reported "Confidence Interval" is actually a Bayesian credible interval.
PrimaryMortality Event Rate

Mortality is defined as death or death equivalent. A participant is determined to meet the criteria of death equivalent if permanent assisted ventilation (PAV) is used for more than 22 hours per day for more than seven days in a row. The rate of mortality was estimated from a Bayesian shared-parametric model that assumed exponentially distributed survival times.

Time frame:
Baseline through 24 Weeks
Reported as:
Mean · events per month
Mortality Event Rate
events per monthZilucoplanMatching Placebo
Mortality Event Rate0.009 ± 0.0020.008 ± 0.002
SecondaryRespiratory Function

Change in respiratory function as assessed by slow vital capacity (SVC).

Time frame:
Baseline and 24 Weeks
Reported as:
Least squares mean · percent change
Respiratory Function
percent changeZilucoplanMatching Placebo
Respiratory Function-9.66 ± 1.423-8.57 ± 1.159
Statistical analysis
  • Zilucoplan vs Matching Placebo · Mixed Models Analysis · p = 0.5495 · Mean difference (net): -1.09 · 95% CI -4.66 to 2.48Zilucoplan 24-week change from baseline relative to placebo 24-week change from baseline.
SecondaryMuscle Strength

Change in muscle strength as measured isometrically using hand-held dynamometry (HHD).

Time frame:
Baseline and 24 Weeks
Reported as:
Least squares mean · percent change
Muscle Strength
percent changeZilucoplanMatching Placebo
Muscle Strength-26.20 ± 2.671-25.16 ± 2.236
Statistical analysis
  • Zilucoplan vs Matching Placebo · Mixed Models Analysis · p = 0.7602 · Mean difference (net): -1.04 · 95% CI -7.73 to 5.65Zilucoplan 24-week change from baseline relative to placebo 24-week change from baseline.
SecondaryNumber of Participants That Experienced Death or Death Equivalent

The number of participants who died or met the criterion for a death equivalent from the date of their baseline visit to the end of the Week 24 visit window (generally 175 days after baseline). The death equivalent criterion is use of permanent assisted ventilation (PAV) for more than 22 hours per day for more than 7 days in a row.

Time frame:
Baseline through 24 Weeks
Reported as:
Count of participants · Participants
Number of Participants That Experienced Death or Death Equivalent
ParticipantsZilucoplanMatching Placebo
Number of Participants That Experienced Death or Death Equivalent66
Statistical analysis
  • Zilucoplan vs Matching Placebo · Log Rank · p = 0.6891

Adverse events

Collected over Up to 35 weeks after participant signed Master Protocol consent.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zilucoplan5/122 (4.1%)25/122 (20.5%)115/122 (94.3%)
Matching Placebo2/40 (5%)3/40 (7.5%)37/40 (92.5%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventZilucoplanMatching Placebo
Respiratory FailureRespiratory, thoracic and mediastinal disorders6/1221/40
GastroenteritisInfections and infestations0/1221/40
Cardiac arrestCardiac disorders1/1221/40
Sudden deathGeneral disorders0/1221/40
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders3/1220/40
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/1220/40
COVID-19Infections and infestations2/1220/40
Generalised oedemaGeneral disorders2/1220/40
Increased upper airway secretionRespiratory, thoracic and mediastinal disorders1/1220/40
ConstipationGastrointestinal disorders1/1220/40
Most frequent other events
Showing 10 of 35
Most frequent other events
EventZilucoplanMatching Placebo
FallInjury, poisoning and procedural complications39/1229/40
Muscular weaknessNervous system disorders29/1228/40
NeuromyopathyNervous system disorders22/1225/40
Injection site bruisingInjury, poisoning and procedural complications22/1226/40
Injection site painInjury, poisoning and procedural complications18/1222/40
FatigueGeneral disorders17/1225/40
Urinary tract infectionInfections and infestations6/1225/40
Decreased appetiteMetabolism and nutrition disorders6/1225/40
HeadacheNervous system disorders14/1224/40
ConstipationGastrointestinal disorders13/1223/40

Baseline characteristics

Baseline Analysis Population includes only placebo participants from the Regimen A Efficacy Regimen Only (ERO) sample; shared placebo participants from other regimens are not included in the Baseline Analysis Population.

Age, Continuous
Age, Continuous(years)ZilucoplanMatching PlaceboTotal
Mean59.5 ± 10.7757.3 ± 12.6958.9 ± 11.27
Sex: Female, Male
Sex: Female, Male(Participants)ZilucoplanMatching PlaceboTotal
Female471663
Male752499
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ZilucoplanMatching PlaceboTotal
Hispanic or Latino729
Not Hispanic or Latino11337150
Unknown or Not Reported213
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ZilucoplanMatching PlaceboTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American202
White11537152
More than one race000
Unknown or Not Reported437
El Escorial Diagnosis
El Escorial Diagnosis(Participants)ZilucoplanMatching PlaceboTotal
Clinically Definite ALS441660
Clinically Probable ALS38745
Clinically Probable ALS - Laboratory Supported351348
Clinically Possible ALS549
Time Since Symptom onset at Baseline
Time Since Symptom onset at Baseline(months)ZilucoplanMatching PlaceboTotal
Mean21.4 ± 8.3222.4 ± 8.9521.7 ± 8.46
Delay in ALS Symptom Onset and Diagnosis
Delay in ALS Symptom Onset and Diagnosis(months)ZilucoplanMatching PlaceboTotal
Mean10.5 ± 6.3910.5 ± 5.9810.5 ± 6.28
ALS Onset Location
ALS Onset Location(Participants)ZilucoplanMatching PlaceboTotal
Bulbar21627
Limb9933132
Multiple011
Respiratory202

10 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Healey Center for ALS at Mass General
    Boston, Massachusetts 02114, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Apr 2022, 20 months.

Results were first posted in Jul 2023, 1 year 3 months after primary completion.

Of 22 phase 2/3 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 109. This study's 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2020
First posted
Jun 18, 2020
StartActual
Jul 29, 2020
Primary completionActual
Apr 13, 2022
CompletionActual
May 4, 2022
Results first posted
Jul 25, 2023
Last update
Jul 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04436497
Lead sponsor
Merit E. Cudkowicz, MD
Collaborators
Ra Pharmaceuticals
Responsible party
Merit E. Cudkowicz, MD (Chief, Neurology Department, Massachusetts General Hospital) — Sponsor-investigator
First posted
Jun 18, 2020
Start date
Jul 29, 2020
Primary completion
Apr 13, 2022
Completion
May 4, 2022
Results posted
Jul 25, 2023
Last update
Jul 25, 2023

Study contacts

Merit Cudkowicz
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zilucoplan

Start the discussion